A ranked, functional answer for your patient's own tumor, to find the best treatment option.
cResponse™ tests your patient's live tumor tissue against the treatment options you're already considering, before they start one, so the decision is grounded in how their tumor actually responds, in about 14 business days, not in population averages or a genomic snapshot alone.
Most treatment decisions are still made against population-level statistics, how a drug performed across a trial cohort, not against how this specific patient's tumor behaves. For many treatment classes, that means response rates well under 50%, applied to an individual case as a best estimate rather than a tested answer.
Genomic profiling narrows the field, but it doesn't close the gap. Sequencing is highly sensitive at detecting alterations, roughly 92% of sequenced solid tumor patients have at least one, but only around 26% of those findings lead to an actual targeted therapy recommendation, and overall direction coverage from NGS alone lands around 24%, roughly 1 in 4 patients sequenced. For the rest, a genomic finding tells you what's in the tumor without telling you what will work on it.
What's missing is a way to verify efficacy before committing to a regimen, and to weigh that against the adverse events a patient will face if it doesn't work. cResponse™ is built for exactly that gap: a ranked, functional answer across the options under consideration, grounded in how the patient's own tumor responds, not a population average or a genomic inference.
High treatment decision complexity, multiple guideline-recommended options
Low reported treatment response rates (ORR < 50%)
Significant or severe side effects associated with treatment options
Rapid disease progression
Early use of cResponse™ helps avoid rapid deterioration and transition to later-line treatments with lower ORR and shorter PFS.
Our 2026 test menu covers 25 strategic indications across metastatic, adjuvant, and neoadjuvant settings, but the menu isn't exhaustive. We can work with you on any decision junction where these conditions occur. See the full 2026 test menu →
CE marked,
ISO 15189:2022 Medical Laboratories
Prediction accuracy, PPV & NPV
against clinical outcomes
Applicable to
all solid tumors
Applicable to all therapy
classes and combinations
Proceed, now with a tested result behind the choice rather than a guideline default alone.
Room to choose on tolerability, sequence, or cost among tested-effective options.
The multi-drug comparison identified an option that cleared the threshold. Grounds to switch to a tested-effective alternative before an ineffective line is spent.
Known before treatment starts: it spares ineffective, toxic cycles and directs attention to other paths, including clinical trials or a timely move to supportive and palliative care.
Clinical outcome follow-up within this study re-confirmed the test's 90%+ PPV and NPV in routine practice.
Discuss cResponse™ with your patient and place an order.
A fresh, 16G biopsy is taken. Archived tissue can't be used.
Our courier collects the sample the same day it's taken.
You provide us with a list of up to 8 drugs you would like to test for your patient.
Tissue is tested against the drug options you specify.
A ranked report is delivered to you in ~14 business days.
Most oncologists won't take on the professional risk of prescribing outside NCCN guidance, and cResponse™ isn't built to ask that of you. The panel is designed around the options already on the table for your patient's diagnosis, on-label first, so the result ranks among choices you'd already be considering rather than arguing for one you wouldn't.
Sometimes the result points to a gentler option, sometimes to a more aggressive one, but always within guideline-supported choices for that indication.
No. cResponse™ is a functional layer that sits on top of standard of care. Where genomic testing ends, for most patients, most of the time, functional testing begins. We can also run the genomic sequencing component ourselves for a single, integrated workup.
Panels are built around on-label options for the diagnosis. We work with all approved and reimbursed drugs, so that when a therapy is found promising it can be accessed and used by the patient. We can discuss whether an off-label or investigational compound can be included.
cResponse™ preserves the intact human tumor microenvironment, immune components included, rather than reconstructing it. See the comparison table on the Platform page for a full breakdown against PDX, organoid, and 2D models.
Up to 10 arms from a single tissue sample.
Our clinical support team can help you determine the right panel and answer questions about a specific case before you order.
Bring us a case and we'll confirm eligibility, sample requirements, and the panel of options to test.
Email us →25 strategic indications across metastatic, adjuvant, and neoadjuvant settings.
View menu →Publications, posters, and concordance studies behind the 90%+ PPV and NPV against clinical outcomes.
See evidence →For institutions looking to integrate functional testing into routine practice or a clinical study.
Partner with us →